Skip to main content
SpringerLink
Log in

Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Ceftriaxone (CTRX) is a known cause of biliary pseudolithiasis (BPL) mainly in children. Biliary elimination of CTRX increases in patients with renal dysfunction. However, the influence of renal dysfunction on the incidence of CTRX-associated BPL has not been well investigated. The aim of this study was to investigate the cumulative incidence of CTRX-associated BPL in adults and to assess if renal dysfunction is a risk factor.

Methods

We retrospectively analyzed the medical records of 478 patients treated with CTRX to assess the incidence and risk factors of CTRX-associated BPL. We examined age, sex, body weight, dosage, and duration of CTRX therapy, and the concentrations of serum creatinine, estimated glomerular filtration rate (eGFR), albumin, and serum calcium in all the patients. The cumulative incidence of BPL was calculated using a competing risk model. The multivariate analysis of each variable for the development of BPL was assessed by a Cox proportional hazards model.

Results

A total of 362 patients (75.7%) had renal dysfunction (eGFR: < 60 mL/min). The cumulative incidence of BPL in patients with renal dysfunction was significantly higher than that in patients with normal kidney function (4.1 vs. 0.6%, p = 0.017). Renal dysfunction (Hazard ratio (HR) 8.14, 95% CI 1.05–63.0, p = 0.045) and female sex (HR 5.35, 95% CI 1.17–24.5, p = 0.031) were independent risk factors of CTRX-associated BPL, which was confirmed using multivariate analysis (renal dysfunction: HR 7.93, 95% CI 1.04–60.5, p = 0.046) (female sex HR 4.65, 95% CI 1.03–21.1, p = 0.046).

Conclusions

Renal dysfunction is an independent risk factor of CTRX-associated BPL in adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982;10:207–15.

    Article  PubMed  CAS  Google Scholar 

  2. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469–527.

    Article  PubMed  CAS  Google Scholar 

  3. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100:1665–70.

    Article  PubMed  CAS  Google Scholar 

  4. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990;99:1772–8.

    Article  PubMed  CAS  Google Scholar 

  5. Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis. 1986;5:708–10.

    Article  PubMed  CAS  Google Scholar 

  6. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2:1411–3.

    Article  PubMed  CAS  Google Scholar 

  7. Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990;322:141–7.

    Article  PubMed  CAS  Google Scholar 

  8. Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, et al. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr. 1999;88:1352–5.

    Article  PubMed  CAS  Google Scholar 

  9. Palanduz A, Yalcin I, Tonguc E, Guler N, Ones U, Salman N, et al. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2000;28:166–8.

    Article  PubMed  CAS  Google Scholar 

  10. Ozturk A, Kaya M, Zeyrek D, Ozturk E, Kat N, Ziylan SZ. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol. 2005;46:112–6.

    Article  PubMed  CAS  Google Scholar 

  11. Biner B, Oner N, Celtik C, Bostancioglu M, Tuncbilek N, Guzel A, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006;34:217–22.

    Article  PubMed  Google Scholar 

  12. Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi. 1996;19:50–4.

    PubMed  CAS  Google Scholar 

  13. Soysal A, Erasov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. Turk J Pediatr. 2007;49:404–7.

    PubMed  Google Scholar 

  14. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet. 1989;2:165.

    Article  PubMed  CAS  Google Scholar 

  15. Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother. 1990;34:1146–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Cometta A, Gallot-Lavallee-Villars S, Iten A, Cantoni L, Anderegg A, Gonvers JJ, et al. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother. 1990;25:689–95.

    Article  PubMed  CAS  Google Scholar 

  17. Becker CD, Fischer RA. Acute cholecystitis caused by ceftriaxone stones in an adult. Case Rep Med. 2009;2009:132452.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol. 1991;86:1251–4.

    PubMed  CAS  Google Scholar 

  19. Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy. 2005;25:1389–95.

    Article  PubMed  Google Scholar 

  20. Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E. Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther. 1983;33:633–41.

    Article  PubMed  CAS  Google Scholar 

  21. Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int. 2004;46:322–4.

    Article  PubMed  Google Scholar 

  22. Sasaki Y, Aoki S, Aoki K, Achiwa K, Yama T, Kubota M, et al. Acute pancreatitis associated with the administration of ceftriaxone in an adult patient. Nihon Shokakibyo Gakkai Zasshi. 2009;106:569–75.

    PubMed  Google Scholar 

  23. Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med. 1984;77:26–32.

    PubMed  CAS  Google Scholar 

  24. Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother. 1983;24:529–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Rivera M, Garcia-Herrera AL, Burguera V, Sosa-Barrios H, Palomares JR, Quereda C. Ceftriaxone-associated gallbladder pseudolithiasis in a PD patient. Perit Dial Int. 2011;31:97–9.

    Article  PubMed  Google Scholar 

  26. Kutuya N, Ozaki Y, Okazaki T. A symptomatic child with ceftriaxone-associated biliary pseudolithiasis. J Med Ultrason. 2008;35:125–8.

    Article  Google Scholar 

  27. Robertson FM, Crombleholme TM, Barlow SE, Verhave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics. 1996;98:133–5.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by the Okinaka Memorial Institute for Medical Research.

Author information

Authors and Affiliations

  1. Department of Nephrology Center, Toranomon Hospital, 2-2-2 Toranomon, Minatoku, 105-8470, Japan

    Aya Imafuku, Naoki Sawa, Akinari Sekine, Masahiro Kawada, Rikako Hiramatsu, Masayuki Yamanouchi, Eiko Hasegawa, Noriko Hayami, Jyunichi Hoshino, Yoshifumi Ubara & Kenmei Takaichi

  2. Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minatoku, 105-8470, Japan

    Naoki Sawa

Authors
  1. Aya Imafuku
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoki Sawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akinari Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiro Kawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rikako Hiramatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayuki Yamanouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eiko Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Noriko Hayami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jyunichi Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshifumi Ubara
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kenmei Takaichi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aya Imafuku.

Ethics declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB Approval Number 994) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Imafuku, A., Sawa, N., Sekine, A. et al. Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction. Clin Exp Nephrol 22, 613–619 (2018). https://doi.org/10.1007/s10157-017-1493-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-017-1493-7

Keywords

Search

Navigation